|
|
News Breaks | | | | March 11, 2013 | | 09:31 EDT |  | ABT | Abbott announces long-term results for Absorb BVS
Abbott announced positive long-term results for the company's innovative Absorb Bioresorbable Vascular Scaffold. Three-year results from 101 patients in the second stage of the ABSORB trial were presented at the 62nd Annual Scientific Session of the American College of Cardiology in San Francisco. Absorb is commercially available in Europe as well as other international markets and is an investigational device in the United States. Results from the ABSORB trial presented at ACC showed the rate of major adverse cardiovascular events in 101 patients was 10% at three years, similar to a comparative set of data with a best-in-class drug eluting stent at the same follow-up period. MACE is a combined endpoint that includes heart attack, death due to heart-related causes, or re-blockage of the blood vessel resulting in symptoms requiring the need for additional procedures at the original site of scaffold implantation. Also, at a recent PCR meeting in Rotterdam, data were presented from the ABSORB EXTEND study, a single-arm trial evaluating Absorb in patients with more complex heart disease than the ABSORB trial. Data from 450 patients enrolled in this trial showed that the rates of MACE at one year were slightly lower than a comparative set of data with a best-in-class drug eluting stent at the same follow-up period. In an analysis of 119 patients with diabetes from the ABSORB EXTEND trial, rates of MACE were comparable between patients with and without diabetes, a promising finding as event rates are typically higher in patients with diabetes when compared to patients without diabetes. | |
|
News For ABT From The Last 14 Days Check below for free stories on ABT the last two weeks. |
|
|
| May 23, 2013 | | 08:14 EDT |  | ABT | Carter's
Global Consumer Products Analysts discuss the possibility of China retiring the one-child policy within the year and potential implications for consumer products on an Analyst/Industry conference call. Relevant covered companies JNJ, PG, PFE, ABT, KMB, MJN and CRI which may be impacted and discussed on the Analyst/Industry conference call to be held on May 23 at 10 am. | | | May 22, 2013 | | 07:28 EDT | | ABT | UBS to host a conference
Global Healthcare Services Conference is being held in New York on May 20-22 with webcasted company presentations to begin on May 22 at 8 am; not all company presentations may be webcasted. Webcast Link | | | May 21, 2013 | | 08:03 EDT | | ABT | Abbott announces CE Mark for coronary drug eluting stent
 Subscribe for More Information | | | May 20, 2013 | | 10:11 EDT |  | ABT | On The Fly: Analyst Upgrade Summary
Subscribe for More Information | | | 06:01 EDT | | ABT | Abbott upgraded to Buy from Neutral at Goldman
Goldman upgraded Abbott to reflect accelerating growth driven by emerging markets, better growth and product mix, new product launches, and market share gains. Price target raised to $44 from $38. | | | May 9, 2013 | | 07:04 EDT | | ABT | Abbott announces CE Mark for A1c test
Subscribe for More Information | |
|
|
|
|
|
|
